<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201577</url>
  </required_header>
  <id_info>
    <org_study_id>09GA014</org_study_id>
    <nct_id>NCT01201577</nct_id>
  </id_info>
  <brief_title>Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals</brief_title>
  <official_title>Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has recently been discovered that bacteria are able to communicate using specialised&#xD;
      molecules known as Quorum Sensing Signalling Molecules (QSSMs). An accumulation of QSSMs in&#xD;
      their surrounding environment allow for the bacteria to quantify the size of colonies. At&#xD;
      specific colony sizes the concentration of QSSMs reaches a critical threshold leading to the&#xD;
      activation of genes that cause an infection. It is by this mechanism that bacteria within a&#xD;
      colony coordinate behaviour to activate infectivity when colony sizes are large enough to&#xD;
      withstand defensive measures from the host's immune system. A disruption of quorum sensing&#xD;
      may reduce the severity of infection and this has led to the development of inhibitors of&#xD;
      quorum sensing as a new strategy in antibacterial therapy.&#xD;
&#xD;
      QSSMs are also thought to facilitate infection by other mechanisms and are able to influence&#xD;
      the number and function of a specific type of immune cell known as an 'antigen presenting&#xD;
      cell'. These cells are pivotal in allowing the immune system to recognise components of&#xD;
      bacteria as foreign and thereby mount the appropriate response. It was found that large&#xD;
      numbers of these types of cells underwent programmed cell death (cell suicide) in the&#xD;
      presence of QSSMs compared to when QSSMs were absent. This mirrors the situation in blood&#xD;
      sampled from patients with severe infections where there is a greater proportion of cell&#xD;
      deaths among antigen presenting cells than other types of immune cell.&#xD;
&#xD;
      This study aims to establish in healthy volunteers, the mechanisms by which QSSMs affect&#xD;
      immune cells and facilitate the spread of infection. Antibiotic administration in humans can&#xD;
      alter the environment of the intestine and can lead to an overgrowth of harmful bacteria to&#xD;
      potentially cause an infection. Probiotics supplements can prevent bacterial overgrowth and&#xD;
      potentially reduce infective complications. The mechanism, which we aim to clarify, may&#xD;
      involve changes in both the production of QSSMs and the function of immune cells.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
        1. Antibiotic use alters gut flora, leading to the appearance in the systemic circulation&#xD;
           of bacterial QSSMs and changes in immune function of the host.&#xD;
&#xD;
        2. Probiotics and/or prebiotics have beneficial effects by preserving the normal resident&#xD;
           gut flora, thereby, modulating bacterial QSSMs and preserving the immune function of the&#xD;
           host.&#xD;
&#xD;
      Aims&#xD;
&#xD;
      The aims of our study are 2 fold:&#xD;
&#xD;
        1. Firstly, to study the effect of orally administered antibiotic on QSSMs (in faeces and&#xD;
           blood) and on innate and adaptive immunity in healthy humans.&#xD;
&#xD;
        2. Secondly, to study the effect of orally administered combinations of prebiotic,&#xD;
           probiotic and antibiotic on QSSMs (in faeces and blood) and on innate and adaptive&#xD;
           immunity in healthy humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum QSSM level</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell Th1/Th2 ratio</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Quorum Sensing</condition>
  <condition>Prebiotics</condition>
  <condition>Probiotics</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Placebo/Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Prebiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic/Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum BB536</intervention_name>
    <description>2 capsules od</description>
    <arm_group_label>Placebo/Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active hexose correlated compound (AHCC)</intervention_name>
    <description>One capsule tds</description>
    <arm_group_label>Placebo/Prebiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)</intervention_name>
    <description>One capsule tds (prebiotic) and two capsules od (probiotic)</description>
    <arm_group_label>Prebiotic/Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Corn starch placebo capsule</intervention_name>
    <description>One capsule tds and two capsules od</description>
    <arm_group_label>Placebo/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>250mg od</description>
    <arm_group_label>Placebo/Placebo</arm_group_label>
    <arm_group_label>Placebo/Prebiotic</arm_group_label>
    <arm_group_label>Placebo/Probiotic</arm_group_label>
    <arm_group_label>Prebiotic/Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male volunteers&#xD;
&#xD;
          -  Age 18-55 years&#xD;
&#xD;
          -  Willing to participate and able to give informed consent&#xD;
&#xD;
          -  Alcohol abstinence during study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers/substance abusers&#xD;
&#xD;
          -  Individuals with diabetes mellitus&#xD;
&#xD;
          -  Oral/Intravenous steroids&#xD;
&#xD;
          -  Allergy to azithromycin&#xD;
&#xD;
          -  Individuals already taking regular medications/probiotics/nutritional supplements&#xD;
&#xD;
          -  Individuals with chronic disease or currently under investigation&#xD;
&#xD;
          -  Individuals with ≤3 bowel movements/week&#xD;
&#xD;
          -  Individuals with ≥2 bowel movements/day&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abeed Chowdhury, MB ChB BSc MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dileep Lobo, MBBS DM FRCS</last_name>
    <role>Study Director</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>September 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2010</study_first_posted>
  <last_update_submitted>May 31, 2011</last_update_submitted>
  <last_update_submitted_qc>May 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dileep Lobob</name_title>
    <organization>University of Nottingham</organization>
  </responsible_party>
  <keyword>Quorum sensing</keyword>
  <keyword>Prebiotics</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Sulfalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

